Abstract 454P
Background
T-DXd is approved as 2L or later treatment for HER2-positive gastric cancer in several countries and is considered emetogenic. Nausea and vomiting affect significantly patient quality of life, leading to poor compliance with further treatment. Therefore, we sought to identify the optimal combination of antiemetic prophylaxis with T-DXd.
Methods
This study was a multicenter, randomized, open-label, non-comparative, Ph2 study to investigate optimal antiemetic prophylaxis for Japanese patients (pts) with gastric cancer treated with T-DXd. The pts were randomized to a doublet regimen (DxR, dexamethasone and palonosetron) or a triplet regimen (TxR, aprepitant in addition to doublet regimen) at a ratio of 1:1; stratified by gender, gastrectomy status, and study site. T-DXd admiration was started at 6.4 mg/kg and the antiemetic prophylaxis was administered from day 1 up to day 5. The primary endpoint was antiemetic complete response (CR, defined no emetic event and no rescue drug) rate to assess control emesis based on patient reported outcomes for 21 days. CR rate in acute phase (0-24hr) and delayed phase (2-21d) were evaluated as a secondary endpoint. With 29 pts per arm, the primary analysis considered a regimen promising if either arm had ≥18 CRs.
Results
A total of 58 pts were eligible for this analysis. Three pts were discontinued follow-up (2 pts in DxR, 1 pt in TxR). Both antiemetic CR rate for 21 days (overall) and CR rate in delayed phase were 41.4% (12/29) for DxR and 37.9% (11/29) for TxR. The antiemetic CR rate in acute phase was 86.2% (25/29) in both regimens. The median first emetic event occurred at 3 day in both regimens.
Conclusions
Both antiemetic prophylaxis regimens did not meet the prespecified antiemetic CR rate. This study, which used patient reported outcome to assess emetic events, has resulted in a higher rate of emetic events compare to monitoring by physicians reported in previous studies. Given the study design and small sample size, further research may help to fully characterize nausea and vomiting with T-DXd in gastric cancer pts.
Clinical trial identification
jRCTs031200336.
Editorial acknowledgement
Legal entity responsible for the study
Yokohama City University Hospital, Epidemiological and Clinical Research Information Network (ECRIN), and Daiichi Sankyo Co., Ltd.
Funding
Daiichi Sankyo Co., Ltd.
Disclosure
K. Oba: Financial Interests, Personal, Invited Speaker: Chugai, Daiichi Sankyo; Financial Interests, Personal, Other, IDMC member: Eisai, Ono pharmaceutical co, Janssen. K. Nishikawa: Financial Interests, Personal, Invited Speaker, Lecture fee: Bristol Myers Squibb, Daiichi Sankyo, EA Pharma, Eli Lilly, MSD, Ono, Taiho, Yakult. H. Maeda: Financial Interests, Personal, Invited Speaker: Tsumura Co; Financial Interests, Personal, Writing Engagement: Igaku-shoin; Non-Financial Interests, Personal, Other, journal editor: Annals of cancer research and therapy; Non-Financial Interests, Personal, Other, research advisory: Japanese foundation of multidisciplinary cancer treatment; Non-Financial Interests, Personal, Other, editorial board: Japanase society of human cells. A. Makiyama: Financial Interests, Personal, Invited Speaker: Eli Lilly, Taiho, Ono, Daiichi Sankyo, Bristol Myers Squibb. T. Oshima: Financial Interests, Personal, Invited Speaker: Taiho, Astellas; Financial Interests, Personal, Writing Engagement: Astellas; Financial Interests, Personal, Other, research grant: Taiho, Kyowa Kirin, Chugai, Nihon kayaku. A. Katayama: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo; Financial Interests, Personal, Stocks/Shares: Daiichi Sankyo. K. Shiosakai: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract